Edgewise Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves patients with Duchenne muscular dystrophy, focusing on ambulatory individuals aged 2 years and older, including subsets amenable to exon skipping therapies and those with nonsense mutation Duchenne. Market segments include patients treated with corticosteroids such as deflazacort and prednisone, patients eligible for exon skipping drugs including EXONDYS 51, AMONDYS 45, VYONDYS 53, and VILTEPSO, as well as patients treated with the gene therapy Elevidys. The primary markets are in the United States, the European Union, and Brazil. Specific customer groups include Duchenne patients aged 2 years and older, ambulatory individuals aged 4 years and older, and non-ambulatory individuals aged 4 years and older, with some FDA indication revisions. Named customers and markets in filings include Catalyst Pharmaceuticals, Inc., Nippon Shinyaku Co. Ltd., PTC Therapeutics, Santhera, and Sarepta Therapeutics, Inc.
Edgewise Therapeutics Clarifies Relationship With Dr. Han Phan Following FDA Warning Boulder, Colo. Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a forerunner in the biopharmaceutical landscape dedicated to combating muscle diseases, has taken a proactive step in addressing its connection to Dr. Han Phan of Rare Disease Research. This announcement comes on the heels of a warning letter issued by the U.S. Food and Drug Administration (FDA) to Dr. Phan on November 27, 2024, following a site inspection that pertained to her work with a different company. In the fast-evolving world of biotechnology, transparency and clarity in communications are vital to establishing trust among stakeholders. Edgewise Therapeut...
Edgewise Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves patients with Duchenne muscular dystrophy, focusing on ambulatory individuals aged 2 years and older, including subsets amenable to exon skipping therapies and those with nonsense mutation Duchenne. Market segments include patients treated with corticosteroids such as deflazacort and prednisone, patients eligible for exon skipping drugs including EXONDYS 51, AMONDYS 45, VYONDYS 53, and VILTEPSO, as well as patients treated with the gene therapy Elevidys. The primary markets are in the United States, the European Union, and Brazil. Specific customer groups include Duchenne patients aged 2 years and older, ambulatory individuals aged 4 years and older, and non-ambulatory individuals aged 4 years and older, with some FDA indication revisions. Named customers and markets in filings include Catalyst Pharmaceuticals, Inc., Nippon Shinyaku Co. Ltd., PTC Therapeutics, Santhera, and Sarepta Therapeutics, Inc.
Sources:
Edgewise Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Edgewise Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Edgewise Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
